Shares of Moderna Inc.
gained 3.5% in trading on Thursday after it said it has completed enrollment of 30,000 participants in the Phase 3 clinical trial for its COVID-19 vaccine candidate. The trial is being conducted in partnership with the National Institutes of Health and the Biomedical Advanced Research and Development Authority. The preclinical company also said that 25,650 participants have received their second and final dose of the experimental vaccine in the late-stage trial, and about one-third of the total number of participants are people of color. Ensuring equitable representation in the coronavirus vaccine trials is an increasingly growing concern for some health care providers given the disproportionate impact of the virus on minorities in the U.S. Moderna’s stock has soared 262.1% so far this year. The S&P 500
in comparison, is up 6.3%.